Anti-MDA5 autoantibodies have been often detected in high titers in patients with CADM and can be used as a biomarker in the clinical diagnosis of dermatomyositis; moreover, the presence of anti-MDA5 autoantibodies is associated with a poor survival prognosis, especially in DM-ILD patients [6, 7]. The gene discussed is IFIH1; the disease is clinically amyopathic dermatomyositis.